PADI2 and Sepsis: Remarkably, both AFM32a and AFM41a treatment improved survival, with AFM41a displaying higher efficacy than AFM32a, highlighting the potential of PAD2 inhibition as a novel therapeutic strategy against PA infection and sepsis.